Unicycive Therapeutics, Inc.
UNCY
$0.64
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 0.00 | 675.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 675.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 0.00 | 0.00 | 675.00K |
| SG&A Expenses | 12.10M | 10.21M | 9.57M | 9.09M | 8.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.12M | 29.17M | 28.86M | 25.78M | 21.45M |
| Operating Income | -32.12M | -29.17M | -28.86M | -25.78M | -20.78M |
| Income Before Tax | -36.73M | -23.00M | -23.24M | -36.93M | -30.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.73 | -23.00 | -23.24 | -36.93 | -30.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.73M | -23.00M | -23.24M | -36.93M | -30.54M |
| EBIT | -32.12M | -29.17M | -28.86M | -25.78M | -20.78M |
| EBITDA | -32.10M | -29.15M | -28.84M | -25.76M | -20.77M |
| EPS Basic | -0.61 | -0.63 | -0.72 | -1.09 | -1.62 |
| Normalized Basic EPS | -0.37 | -0.38 | -0.44 | -0.76 | -0.98 |
| EPS Diluted | -0.83 | -0.85 | -0.94 | -1.09 | -1.62 |
| Normalized Diluted EPS | -0.47 | -0.48 | -0.53 | -0.76 | -0.98 |
| Average Basic Shares Outstanding | 267.46M | 196.60M | 140.29M | 117.61M | 97.96M |
| Average Diluted Shares Outstanding | 323.60M | 252.73M | 196.42M | 117.61M | 97.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.98% | -4.76% | -4.71% | -- | -- |